Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

This Analyst Just Downgraded Moderna Stock. Here's Why.

Citi’s senior analyst Geoff Meacham says investors should reduce exposure to Moderna (MRNA) before the biotech stock comes crashing down in the final quarter of 2026.

Meacham downgraded MRNA this morning to “Sell” and raised his price objective to $80, which nonetheless suggests potential downside of an alarming 60% from current levels.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.